Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.52 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | F9 | P00740 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | SELE | P16581 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12095346 | 0.79 | CYP2A6 (0.53) | CYP2A6SLC9A1ICAM1SELEALDH1A1 | |
| SCHEMBL12095282 | 0.78 | CYP2A6 (0.52) | CYP2A6SLC9A1ICAM1SELEALDH1A1 | |
| SCHEMBL27252542 | 0.78 | CA2 (0.53) | CYP2A6ICAM1SELECA2ALDH1A1 | |
| SCHEMBL12095302 | 0.78 | CYP2A6 (0.52) | CYP2A6SLC9A1ICAM1SELEGPR3 | |
| SCHEMBL12683511 | 0.78 | CYP2A6 (0.54) | CYP2A6ICAM1SELEGPR3ALDH1A1 | |
| SCHEMBL3279792 | 0.74 | SLC9A1 (0.50) | CYP2A6SLC9A1ICAM1SELEMPI | |
| SCHEMBL10757755 | 0.74 | CYP2A6 (0.51) | CYP2A6F9SLC9A1 | |
| SCHEMBL28086653 | 0.74 | CA2 (0.55) | CYP2A6SLC9A1CA2ALDH1A1ALOX15 | |
| SCHEMBL24857860 | 0.71 | PLAU (0.56) | CYP2A6PLAUF9F10SLC9A1 | |
| SCHEMBL12330261 | 0.71 | PLAU (0.51) | PLAUF9F10SLC9A1ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778932-B2 | Dihydro-oxazolobenzodiazepinone compounds, a process for there preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2014-07-15 | — | — | US | disclosed |
| EP-2497774-B1 | Dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds | SERVIER LAB (FR) | 2013-10-16 | — | — | EP | disclosed |
| CN-102675341-A | Dihydro-triazole and benzo two nitrogen heterocyclic ketones compound, processes for their preparation and pharmaceutical compositions comprising these compounds | SERVIER LAB | 2012-09-19 | — | — | CN | disclosed |
| WO-2012120206-A1 | NOVEL DIHYDRO-OXAZOLOBENZODIAZEPINONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2012-09-13 | — | — | WO | disclosed |
| US-20120232065-A1 | DIHYDRO-OXAZOLOBENZODIAZEPINONE COMPOUNDS, A PROCESS FOR THERE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EGIS GYOGYSZERGYAR NYRT (HU) | 2012-09-13 | — | — | US | disclosed |
| EP-2497774-A1 | Dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds | Les Laboratoires Servier (FR) | 2012-09-12 | — | — | EP | disclosed |
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1373240-B1 | RETINOID X RECEPTOR MODULATORS | LILLY CO ELI (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040167160-A1 | Retinoid x receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| EP-1373240-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002071827-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167160-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | CYP2A6 87/4885PLAU 2556/4885F9 1911/4885 |
| US-20080090860-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | CYP2A6 102/4885PLAU 2336/4885F9 1857/4885 |
| US-20120232065-A1 | DIHYDRO-OXAZOLOBENZODIAZEPINONE COMPOUNDS, A PROCESS FOR THERE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GRIN2C, GRIN2B, GRIN2A | CYP2A6 179/4885PLAU 4669/4885F9 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.